• Home
• Research
• Specialized Working Groups
• Chronic Myeloid Leukemia
• Publications

Publications

• Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors
  Atallah E, Mauro MJ, Hochhaus A, Boquimpani C, Minami Y, Maheshwari VK, Saini L, Corbin R, Réa D. J.
  Cancer Res Clin Oncol. 2023 149:6247-6262.
  
  
• First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia
  Balsat M, Alcazer V, Etienne G, Huguet F, Berger M, Cayssials E, Charbonnier A, Escoffre-Barbe M, Johnson-Ansah H, Legros L, Roy L, Delmer A, Ianotto JC, Orvain C, Larosa F, Meunier M, Amé S, Andreoli A, Cony-Makhoul P, Morisset S, Tigaud I, Rea D, Nicolini FE.
  Leuk Res. 2023 130:107308.
  
  
• Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry
  Brioli A, Lomaia E, Fabisch C, Sacha T, Klamova H, Morozova E, Golos A, Ernst P, Olsson-Stromberg U, Zackova D, Nicolini FE, Bao H, Castagnetti F, Patkowska E, Mayer J, Hirschbühl K, Podgornik H, Paczkowska E, Parry A, Ernst T, Voskanyan A, Szczepanek E, Saussele S, Franke GN, Kiani A, Faber E, Krause S, Casado LF, Lewandowski K, Eder M, Anhut P, Gil J, Südhoff T, Hebart H, Heibl S, Pfirrmann M, Hochhaus A, Lauseker M.
  Leukemia. 2024 Mar 28. doi: 10.1038/s41375-024-02204-y.
  
  
• Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry
  Chelysheva E, Apperley JF, Turkina A, Yassin MA, Rea D, Nicolini FE, Barraco D, Kazakbaeva K, Saliev S, Shacham Abulafia A, Al-Kindi S, Byrne J, Robertson HF, Cerrano M, Shmakov R, Polushkina E, de Fabritiis P, Trawinska MM, Abruzzese E.
  Leukemia 2024 [EPub ahead of print].
  
  
• Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukaemia: managing intolerance and resistance
  Claudiani S, Chughtai F, Khan A, Hayden C, Fernando F, Khorashad J, Orovboni V, Scandura G, Szydlo R, Innes A, Apperley JF, Milojkovic D.
  Leukemia 2024 [EPub ahead of print].
  
  
• European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia
  Cross NCP, Ernst T, Branford S, Cayuela JM, Deininger M, Fabarius A, Kim DDH, Machova Polakova K, Radich JP, Hehlmann R, Hochhaus A, Apperley JF, Soverini S.
  2023 Leukemia [EPub ahead of print].
  
  
• Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment-free remission period after imatinib discontinuation: Results of the French Nilo post-STIM study
  Dulucq S, Rigal-Huguet F, Nicolini FE, Cony-Makhoul P, Escoffre-Barbe M, Gardembas M, Legros L, Rousselot P, Liu J, Rea D, De Mas V, Hayette S, Raynaud S, Lacoste-Roussillon C, Robbesyn F, Klein E, Morisset S, Mahon FX, Etienne G.
  Br J Haematol. 2023 201:1116-1124.
  
  
• The outcome of post-transplant asciminib in patients with chronic myeloid leukaemia
  Fernando F,  Innes AJ, Claudiani S, Pryce A, Hayden C, Byrne J, Gallipoli P, Copland M, Apperley JF, Milojkovic D.
  Bone Marrow Transplant 2023 58:826-828.
  
  
• Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects
  Geelen IGP, Gullaksen SE, Ilander MM, Olssen-Strömberg U, Mustjoki S, Richter J, Blijlevens NMA, Smit WM, Gjertsen BT, Gedde-Dahl T, Markevärn B, Koppes MMA, Westerweel PE, Hjorth-Hansen H, Janssen JJWM.
  Ann Hematol. 2023 102:1395-1408.
  
  
• Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL
  Hochhaus A, Réa D, Boquimpani C, Minami AY, Cortes JE, Hughes TP, Apperley JF, Lomaia E, Voloshin S, Turkina A, Kim DW, Abdo A, Fogliatto LM, le Coutre P,  Sasaki K,  Kim DDH,  Saussele S,  Annunziata M,  Chaudhri N, Chee L, García-Gutiérrez V, Kapoor S, Allepuz A, Quenet S, Bédoucha V,  Mauro MJ.
  Leukemia 2023 37:617-626.
  
  
• Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study
  Isfort S, Manz K, Teichmann LL, Crysandt M, Burchert A, Hochhaus A, Saussele S, Kiani A, Göthert JR, Illmer T, Schafhausen P, Al-Ali HK, Stegelmann F, Hänel M, Pfeiffer T, Giagounidis A, Franke GN, Koschmieder S, Fabarius A, Ernst T, Warnken-Uhlich M, Wolber U, Kohn D, Pfirrmann M, Wolf D, Brümmendorf TH; German CML study group.
  Ann Hematol. 2023 Oct;102(10):2741-2752.
  
  
• Dose modification dynamics of ponatinib in patients with chronic-phase chronic 1 myeloid leukemia (CP-CML) from the PACE and OPTIC trials
  Jabbour E, Apperley JF, Cortes J, Rea D, Deininger M, Abruzzese E, Chuah C, DeAngelo DJ, Hochhaus A, Lipton JH, Mauro M, Nicolini F, Pinilla-Ibarz J,  Rosti G, Rousselot P, Shah NP, Talpaz M, Vorog A, Ren X,  Kantarjian H.
  Leukemia 2024 38:475-481.
  
  
• BCR::ABL1 kinase domain mutation testing and clinical outcome in a nationwide chronic myeloid leukemia patient population
  Kockerols C, Valk PJM, Blijlevens NMA, Cornelissen JJ, Dinmohamed AG, Geelen I, Hoogendoorn M, Janssen JJWM, Daenen LGM, Reijden BAV, Westerweel PE.
  Eur J Haematol. 2023 111:938-945.
  
  
• Survival with chronic myeloid leukaemia after failing milestones
  Lauseker M, Hehlmann R, Hochhaus A, Saußele S.
  Leukemia. 2023 Nov;37(11):2231-2236.
  
  
• Practical considerations in the management of patients treated with bosutinib for chronic myeloid leukemia
  Lipton JH, Brummendorf TH, Apperley JF, Cortes JE.
  Annals of Hematology 2024 [EPub ahead of print].
  
  
• The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib
  Machova Polakova K, Albeer A, Polivkova V, Krutska M, Vlcanova K, Curik N, Fabarius A, Klamova H, Spiess B, Waller CF, Brümmendorf TH, Dengler J, Kunzmann V, Burchert A, Belohlavkova P, Mustjoki S, Faber E, Mayer J, Zackova D, Panayiotidis P, Richter J, Hjorth-Hansen H, Kamińska M, Płonka M, Szczepanek E, Szarejko M, Bober G, Hus I, Grzybowska-Izydorczyk O, Wasilewska E, Paczkowska E, Niesiobędzka-Krężel J, Giannopoulos K, Mahon FX, Sacha T, Saußele S, Pfirrmann M.
  Leukemia. 2024 38:318-325.
  
  
• Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results
  Mauro MJ, Hughes TP, Kim DW, Rea D, Cortes JE, Hochhaus A, Sasaki K, Breccia M, Talpaz M, Ottmann O, Minami H, Goh YT, DeAngelo DJ, Heinrich MC, Gómez-García de Soria V, le Coutre P, Mahon FX, Janssen JJWM, Deininger M, Shanmuganathan N, Geyer MB, Cacciatore S, Polydoros F, Agrawal N, Hoch M, Lang F.
  Leukemia. 2023 37:1048-1059.
  
  
• FISH-negative BCR::ABL1-positive e19a2 chronic myeloid leukaemia: the most cryptic of insertions
  May PC, Reid AG, Robinson ME, Khorashad JS, Milojkovic D, Claudiani S; Genomics England Research Consortium; Willis F, Apperley JF, Innes AJ.
  BMC Med Genomics. 2023 16:172.
  
  
• Effect of tyrosine kinase inhibitors on male fertility in patients with chronic phase chronic myeloid leukaemia
  Nesr G, Claudiani S, Milojkovic D, Innes A, Caballes I, Mungozi P, Szydlo R, Lovato S, Jayasena CN, Apperley JF.
  Leukemai and Lymphoma 2024 [EPub ahead of print].
  
  
• Mismatched Related Donor Allogeneic transplantation compared to other donor types for Ph+ Chronic Myeloid Leukemia: a Retrospective Analysis from the Chronic Malignancies Working Party of the EBMT
  Onida F, Gras L, Ge J, Koster L, Hamladji RM. Byrne J, Avenoso D, Aljurf M, Robin M, Halaburda K, Passweg J, Salmenniemi U, Sengeloev H. Apperley JF, Clark A, Reményi P, Morozova E, Craddock C,  Lenhoff S, Ganser A, Lung WK, Perez Martinez A, Hayden PJ, Raj K, Drozd-Sokolowska J, Orti G, de Lavallade H, Yakoub-Agha I, McLornan DP, Chalandon Y.
  British Journal of Haematology 2024 [EPub ahead of print].
  
  
• Graft-versus-Host Disease Prophylaxis with Post Transplant Cyclophosphamide in Chronic Myeloid Leukemia patients undergoing Allogeneic Hematopoietic Cell Transplant from either an Unrelated or Mismatched Related Donor: a comparative study from the Chronic Malignancies Working Party of the EBMT (CMWP-EBMT)
  Ortí G, Gras L, Koster L, Kulagin A, Byrne J, Apperley JF, Kalaburda K, Blau IW, Clark A, Kröger N, Griskevicius L,  Karlson K, Collin M, Bloor A, Angelucci E, Blaise D, Aljurf M, López-Corral L, Sakellari J, Beguin Y, Wrobe T,  de Rosa L,  de Lavallade H, Hayden PJ, McLornan D, Chalandon Y, Yakoub-Agha I.
  Transplant Cell Ther. 2024 30:93.e1-93.e12.
  
  
• Health-related quality of life of patients with resistant/ intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial
  Réa D, Boquimpani C, Mauro MJ, Minami Y, Allepuz A, Maheshwari VK, D'Alessio D, Wu Y, Lawrance R, Narbutas S, Sharf G, Hochhaus A.
  Leukemia. 2023 37:1060-1067.
  
  
• Aleukemic chronic myeloid leukemia without neutrophilia and thrombocytosis at initial presentation: a report from the BCR::ABL1 Pathology Group
  Rivera D, Cui W, Gao J, Peker D, Zhang QY, Dewar R, Qiu L, Konoplev S, Hu Z, Sasaki K,  Jelloul F1, E S, Liu M, Hu A, Fang H, Wang W, Tang G, Apperley JF, Hochhaus A, Cortes JE, Khoury JD, Medeiros LJ, Jabbour E, Hu S.
  Modern Pathology 2023;37:100406.
  
  
• Managing women of childbearing age with chronic myeloid leukemia: safety and treatment considerations
  Robertson HF, Buckton MJ, Apperley JF.
  Expert Rev Hematol. 2023 20:1-8.
  
  
• Are syngeneic donors a viable donor option in allogeneic haematopoietic cell transplantation for MDS? A brief report on behalf of the Chronic Malignancies Working Party of the EBMT and review of current literature
  Robin M, Gras L, Koster L, Saccardi R, Finke J, Forcade E, Rovira M, Kobbe G, Reményi P, Apperley J, et al.
  Bone Marrow Transplant. 2023 Apr 25 [EPub ahead of print].
  
  
• Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study
  Rosti G, Brümmendorf TH, Gjertsen BT, Giraldo-Castellano P, Castagnetti F, Gambacorti-Passerini C, Ernst T, Zhao H, Kuttschreuter L, Purcell S, Giles FJ, Hochhaus A.
  Leukemia. 2024 Jan;38(1):126-135.
  
  
• Dasatinib plus Peg-Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: results of a multicenter phase 2 study (DASA-PegIFN study)
  Roy L, Chomel JC, Guilhot J, Guerci-Bresler A, Escoffre-Barbe M, Giraudier S, Charbonnier A, Dubruille V, Huguet F, Johnson-Ansah H, Lenain P, Ame S, Etienne G, Nicolini FE, Rea D, Cony-Makhoul P, Courby S, Ianotto JC, Legros L, Machet A, Coiteux V, Hermet E, Cayssials E, Bouchet S, Mahon FX, Rousselot P, Guilhot F; French CML Group (FiLMC).
  Br J Haematol. 2023 200:175-186.
  
  
• Measuring chronic myeloid leukaemia TKI-related toxic effects in the real world: a systematic review and critical assessment of content validity of patient-reported outcome measures
  Smit Y, Metsemakers SJJPM, Janssen JJWM, Posthuma EFM, Walraven I, Hermens RPMG, Blijlevens NMA.
  Lancet Haematol. 2023 10:e849-e859.
  
  
• Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study
  Smith BD, Brümmendorf TH, Roboz GJ, Gambacorti-Passerini C, Charbonnier A, Viqueira A, Leip E, Purcell S, Goldman EH, Giles F, Ernst T, Hochhaus A, Rosti G.
  Leuk Res. 2024 Apr;139:107481.
  
  
• Project Confirm: Accelerated Drug Approvals for Chronic Myeloid Leukemia
  Sweet KL, Cortes JE, Apperley JF, Mann M, Mauro MJ, Oehler VG, Ruiz C, Schiffer CA, Ehrlich LA, Pamuk GE, Wynne J, Mehta GU, de Claro RA, Theoret MR, Smith BD, Norsworthy KJ.
  Clin Cancer Res. 2023 29:2179-2183.